Opinion|Videos|April 1, 2025
Building Better Collaboration: Reducing Care Delays in Managing mCRC
Experts discuss proactive steps health care teams, including pharmacists, can take to minimize delays and overcome payer-related barriers when prescribing third-line therapies for metastatic colorectal cancer (mCRC) and how collaboration between health care teams, payers, and manufacturers can be improved to reduce care delays.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What proactive steps can health care teams, including pharmacists, take to minimize delays and overcome payer-related barriers when prescribing third-line therapies?
- How can collaboration between health care teams, payers, and manufacturers be improved to reduce delays in care for patients with mCRC?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
4
From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps
5